HB 2245 – Arizona
Introduced: 2023 Status: Inactive / Dead
The Department Shall Enter Into Partnerships, Consistent With Section 36-4203 In Consultation With Other State Departments As Necessary, To Increase Competition, Lower Prices And Address Shortages In The Market For Generic Prescription Drugs, To Reduce …
HB 239 – Illinois
Introduced: 2017 Status: Inactive / Dead
DRUG MANUFACTURER DISCLOSURES: Requires manufacturers of brand name or generic prescription drugs to notify State purchasers, health insurers, health care service plan providers, pharmacy benefit managers, and the General Assembly of specified increases in drug …
HB 243 (see similar bill HB 710) – Louisiana
Introduced: 2018 Status: Inactive / Dead
PROHIBITS A MANUFACTURER OR WHOLESALE DISTRIBUTOR FROM ENGAGING IN PRICE GOUGING IN THE SALE OF AN ESSENTIAL OFF-PATENT OR GENERIC DRUG. Authorizes the secretary of the La. Dept. of Health to notify the attorney general …
HB 2529 (see companion bill SB 241) – Texas
Introduced: 2023 Status: Inactive / Dead
Relating to written notification provided by drug manufacturers regarding the cause of generic or biosimilar insulin prescription drug unavailability.
HB 2549 – Oklahoma
Introduced: 2021 Status: Inactive / Dead
An Act relating to pharmacy; defining terms; providing for the substitution of an interchangeable biological product for a prescribed biological product under certain conditions; requiring electronic notice of substitution; providing exceptions; directing State Board of …
HB 2556 (see companion bill SB 5995) – Washington
Introduced: 2018 Status: Inactive / Dead
GENERIC PRESCRIPTION DRUG PRICES: Protects consumers and purchasers from excessive increases in generic prescription drug prices, requires a drug manufacture to use a price increase notification form when there is an increase in the wholesale acquisition …
HB 2754 – Oregon
Introduced: 2019 Status: Inactive / Dead
Requires pharmacy or pharmacist to substitute prescribed biological product with interchangeable biological product. Declares emergency, effective on passage.
HB 2755 – Oregon
Introduced: 2019 Status: Inactive / Dead
Requires pharmacy or pharmacist to substitute prescribed brand name drug with generic name drug product and to substitute prescribed biological product with interchangeable biological product. Declares emergency, effective on passage.
HB 276 (see companion bill SB 103) – Georgia
Introduced: 2017 Status: Enacted
RELATING TO THE REGULATION AND LICENSURE OF PHARMACY BENEFIT MANAGERS: authorizes the Commissioner of Insurance to promulgate rules and regulations to prohibit PBMs from requiring the use of mail-order pharmacies. Would ban the PBM practice …
HB 2800 – Oklahoma
Introduced: 2021 Status: Inactive / Dead
An Act relating to insurance; amending Section 5, Chapter 426, O.S.L. 2019 (36 O.S. Supp. 2020, Section 6962), which relates to compliance review; modifying calculation of certain insured’s contribution; defining term; and providing an effective …
HB 2811 – West Virginia
Introduced: 2019 Status: Inactive / Dead
Relating to generic drug products: A BILL to amend and reenact §30-5-12b of the Code of West Virginia, 1931, as amended, relating to generic drug products; and making the provisions retroactive.
HB 3139 – Oklahoma
Introduced: 2020 Status: Inactive / Dead
Pharmacy; interchangeable biological products; effective date. An Act relating to pharmacy; defining terms; providing for the substitution of an interchangeable biological product for a prescribed biological product under certain conditions; requiring electronic notice of substitution; …
HB 3256 – Illinois
Introduced: 2023 Status: In Process
Creates the Affordable Drug Manufacturing Act. Provides that the Department of Public Health shall enter into partnerships to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the …
HB 33 – Alabama
Introduced: 2019 Status: Inactive / Dead
Relating to pharmacists and the requirements for prescriptions and the dispensing of prescriptions; to amend Section 34-23-8 of the Code of Alabama 1975, to specify that, unless a physician or other practitioner indicates otherwise, a …
HB 345 – Montana
Introduced: 2021 Status: Inactive / Dead
Establish Prescription Drug Pay-for-Delay Transparency Act. Each manufacturer of a brand-name prescription drug that is transacting business in this state or whose brand-name prescription drugs are otherwise sold or distributed in this state shall notify …
HB 346 – Kentucky
Introduced: 2023 Status: Inactive / Dead
Amend KRS 304.17A-163 to permit insurers to require insureds to try biosimilar biological products prior to providing coverage for the equivalent branded prescription drug under certain circumstances; amend KRS 217.814 to define biosimilar biological product; …